<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25625100</article-id><article-id pub-id-type="pmc">4298880</article-id><article-id pub-id-type="publisher-id">ABR-3-261</article-id><article-id pub-id-type="doi">10.4103/2277-9175.148234</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The effect of oral vitamin D on serum level of N-terminal pro-B-type natriuretic peptide</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Seirafian</surname><given-names>Shiva</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Haghdarsaheli</surname><given-names>Yalda</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Mortazavi</surname><given-names>Mojgan</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Mohsen</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Moeinzadeh</surname><given-names>Firouzeh</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Internal Medicine and Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mojgan Mortazavi, Department of Internal Medicine and Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="m_mortazavi@med.mui.ac.ir">m_mortazavi@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2014</year></pub-date><volume>3</volume><elocation-id>261</elocation-id><history><date date-type="received"><day>06</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2014 Seirafian</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The risk of cardiovascular disease in dialysis patients is higher than the general population. Vitamin D receptors exist in myocardium inhibit cardiac hypertrophy. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a neurohormone secreted by the heart in response to ventricular mass increase. This study aimed to evaluate the effect of oral vitamin D on serum level of pro-B-type natriuretic peptide (pro-BNP) in peritoneal dialysis patients.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>In a randomized clinical trial, 84 peritoneal dialysis patients (49 males and 35 females) were randomly divided into two groups. The intervention group received 50000 units oral vitamin D per week, for 12 weeks if 25-hydroxy-vitamin D level was &#x0003c;10 ng/ml and for 8 weeks if it was between 10 ng/ml and 30 ng/ml. The control group received placebo. Parathyroid hormone, calcium, phosphor, 25-hydroxy-vitamin D, albumin and NT-pro-BNP were evaluated before and after the study.</p></sec><sec id="st3"><title>Results:</title><p>The mean serum level of pro-BNP in patients receiving vitamin D and placebo group before the study was 875 pg/ml and 793 pg/ml, respectively. There was 895.9 pg/ml in the intervention group and 736.7 pg/ml in the control group (<italic>P</italic> = 0.7). Mean serum level of 25(OH) D in patients receiving oral vitamin D and placebo group before the study was 16.9 ng/ml and 31.9 ng/ml, respectively. There was 28.9 ng/ml in the intervention group and 12.9 ng/ml in the control group (<italic>P</italic> = 0.001). There were no significant differences regarding other indices (Alb, P, Ca, intact parathyroid hormone) between two groups.</p></sec><sec id="st4"><title>Conclusion:</title><p>Vitamin D did not significantly change the serum level of pro-BNP in peritoneal dialysis patients.</p></sec></abstract><kwd-group><kwd>N-terminal pro-B-type natriuretic peptide</kwd><kwd>peritoneal dialysis</kwd><kwd>vitamin D</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Patients with chronic dialysis experience disorders that reduce their quality of life and life expectancy. Among these complications, the prevalence of cardiovascular problems is higher.[<xref rid="ref1" ref-type="bibr">1</xref>] The prevalence of hypertension, left ventricular hypertrophy, ischemic heart disease and heart failure are higher in patients with chronic renal failure undergoing dialysis. Their cardiovascular mortality is about 10-30 times more than normal populations. Empirical evidence shows that reduction of vitamin D can cause cardiac structural and functional damage.[<xref rid="ref2" ref-type="bibr">2</xref>]</p><p>Nutritional vitamin D deficiency is highly prevalent. Its prevalence among the general population is 30-50%,[<xref rid="ref3" ref-type="bibr">3</xref>] which is enhanced in hospitalized patients up to 90%.[<xref rid="ref4" ref-type="bibr">4</xref>] In patients with kidney failure undergoing dialysis, vitamin D level (25-hydroxy vitamin D) is also decreased.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref><xref rid="ref7" ref-type="bibr">7</xref>] Causes for vitamin D reduction include the loss of binding protein with vitamin D in urine, malnutrition, decreased reabsorption of filtered 25-hydroxy vitamin D in the proximal tubule and loss of vitamin D during dialysis (which is more common among peritoneal dialysis patients).[<xref rid="ref8" ref-type="bibr">8</xref>]</p><p>Vitamin D receptors are present at myocardium[<xref rid="ref9" ref-type="bibr">9</xref>] and their stimulation can prevent the growth of myocardium and hypertrophy and can decrease secretion of cardiac B-type natriuretic peptide (BNP) in the myocytes of the atria and ventricles.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref10" ref-type="bibr">10</xref><xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref>] The active vitamin D can act as a negative regulator of the renin angiotensin.[<xref rid="ref15" ref-type="bibr">15</xref>] The reduction and cessation of vitamin D intake in rats caused cardiac hypertrophy by activating renin angiotensin system and cardiac natriuretic peptide. The treatment of these rats by angiotensin converting enzyme inhibitor (captopril) resulted in reduction of cardiac hypertrophy and normalization of atrial natriuretic peptide (ANP).[<xref rid="ref16" ref-type="bibr">16</xref>]</p><p>In another study on rats, activation of vitamin D receptors suppressed the production and release of BNP and ANP in cardiomyocytes. It is more than a decade that BNP is used as a marker for cardiac failure.[<xref rid="ref17" ref-type="bibr">17</xref>]</p><p>During the process of BNP secretion of cardiac myositis the pro-B-type natriuretic peptide (pro-BNP) precursor consisting of 108 amino acids splits into BNP peptide with 32 amino acids and N-terminal pro-BNP (NT-Pro-BNP) fragment with 76 amino acids.[<xref rid="ref18" ref-type="bibr">18</xref>] It is a response to the increased stress in the ventricular wall caused by diastolic pressure and pressure overload. BNP and NT-pro-BNP are markers of severity and prognosis of acute coronary syndrome and heart failure.[<xref rid="ref19" ref-type="bibr">19</xref>]</p><p>It seems that in the natriuretic peptide family the NT-pro-BNP is the best predictor of clinical outcome and the best marker for the increase of extracellular volume. This peptide is bigger considering its structure and it has longer half-life than BNP and it is easier to be measured.[<xref rid="ref20" ref-type="bibr">20</xref>]</p><p>The most common cause of death in chronic dialysis patients is cardiovascular events. Identification and treatment of these complications significantly contributes to patients&#x02019; health and reduces health care costs. Based on the effect of vitamin D on the function and structure of the heart, considering NT-pro-BNP as a cardiac diagnostic and prognostic marker and taking into account that no study has been conducted so far on evaluating the effect of vitamin D on NT-pro-BNP serum level, this study was conducted to investigate this relationship among the peritoneal dialysis patients.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>The present study was a double-blind clinical trial conducted at the Al-Zahra University Hospital in Isfahan, Iran. At first, information regarding age, gender, cause of primary renal failure, duration of dialysis and medications including calcium carbonate, sevelamer and calcitriol were collected. Inclusion criteria included peritoneal dialysis for at least 3 months, age over 18 years, not being treated with vitamin D during the last 3 months, absence of malignancy and patient satisfaction. Exclusion criteria included recent history of heart failure (past 3 months), vitamin D level more than 30 ng/ml, Ca &#x000d7; P product more than 55 and lack of patient consent. Sample size was calculated to 84 patients.</p><p>After obtaining informed consent from the patients, blood samples were taken during morning dialysis. Immediately after obtaining the samples they were sent to laboratory for intact parathyroid hormone (iPTH), Ca, P, 25(OH) vitamin D, albumin and pro-BNP measurement. Samples were immediately centrifuged at 4&#x000b0;C in the laboratory and were maintained at &#x02212;20&#x000b0;C. 25(OH) vitamin D was considered insufficient if the level was 10-30 ng/ml; if lower than 10 ng/ml it was deemed deficient and values higher than 30 ng/ml was considered as sufficient.[<xref rid="ref9" ref-type="bibr">9</xref><xref rid="ref22" ref-type="bibr">22</xref>] In the intervention group, in case of being deficient, 50,000 unit vitamin D pearl manufactured by Zahravi Company, Tabriz, IRAN was given weekly for 12 weeks. For subjects with insufficient level, 50,000 unit vitamin D with a similar pattern was given for 8 weeks.[<xref rid="ref21" ref-type="bibr">21</xref>] The control group was given placebo from Zahravi Company using similar manner. The level of 25(OH) vitamin D, pro-BNP, iPTH, Ca, P, Alb was assessed in the same laboratory after 12 weeks.[<xref rid="ref10" ref-type="bibr">10</xref>] Calcium, phosphorus and albumin levels of patients were assessed in the middle of study for adjusting the dosage of medications. To measure the pro-BNP, Novogent kit (Made in UK) and to assess vitamin D, IDS kit which both use Elisa method was employed.</p><sec id="sec2-1"><title>Statistical analysis</title><p>This study has approved by Isfahan Kidney Diseases Research Center (project No. 290369) and ethical committee of Isfahan University of Medical Sciences. This study was registered in Iranian registry of clinical trials with ID number: IRCT201212142417N10.</p><p>Kolmogorov-Smirnov test was used to evaluate data normality when the variable was continues. Chi-square test, Fisher's test and Student's <italic>t</italic>-test were used for analysis. Data were analyzed by SPSS 20 (SPSS, Inc., Chicago, IL, USA). The findings of this research were results of project number 290369, Isfahan University of Medical Sciences.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>A total of 89 patients participated in the study. All candidates were randomized into either vitamin D therapy (<italic>n</italic> = 49) or placebo therapy (<italic>n</italic> = 40). During the study period, one patient died in both groups, modality of dialysis change in one patient in the placebo group and two patient in vitamin D group. A total of 84 patients completed the study [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow diagram of the study process and patient selection</p></caption><graphic xlink:href="ABR-3-261-g001"/></fig><p>Nearly 56.5% of the patients were entered in the intervention group receiving vitamin D and 60.5% were in the placebo group. This difference was not statistically significant. Some demographic data like mean age and frequency of dialysis are included in <xref ref-type="table" rid="T1">Table 1</xref>. The average calcium carbonate at baseline in patients treated with vitamin D was 1050 mg and in the placebo group it was 800 mg. After the study, this amount was 1025 and 750 mg respectively (<italic>P</italic> = 0.01). Changes in average calcitriol usage before and the end of study in patients treated with vitamin D and placebo group showed no significant changes like for sevelamer. Details of these data as shown in <xref ref-type="table" rid="T2">Table 2</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>General characteristics of peritoneal dialysis in the study group</p></caption><graphic xlink:href="ABR-3-261-g002"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Mean and SD of medications used for patients before and after the study</p></caption><graphic xlink:href="ABR-3-261-g003"/></table-wrap><p>Mean pro-BNP before the study in patients receiving vitamin D and placebo group were 895.1 pg/ml and 793.3 pg/ml and after the study it was 895.9 and 736.7 pg/ml, respectively. The differences were statistically significant neither within group nor between groups comparison [<xref ref-type="fig" rid="F2">Figure 2</xref>]. Mean vitamin D at baseline in patients receiving vitamin D and placebo group was 16.9 ng/ml and 19.5 ng/ml, respectively. After the study, it was 31.9 ng/ml in the intervention group and 12.9 ng/ml in the placebo group. The mean difference before and after the study in both groups was statistically significant (<italic>P</italic> = 0.001) [<xref ref-type="fig" rid="F3">Figure 3</xref>]. There was no significant difference regarding other indices (P, Ca, Alb and iPTH) between the two groups [Tables <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T3">4</xref>]. In addition to the assessments in the beginning and the end of the study, the changes in calcium and phosphorus were also measured 1 month after the study [<xref ref-type="table" rid="T5">Table 5</xref>].</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Changes of pro-B-type natriuretic peptide during the study in the control and intervention groups</p></caption><graphic xlink:href="ABR-3-261-g004"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Changes of vitamin D during the study in the control and intervention groups</p></caption><graphic xlink:href="ABR-3-261-g005"/></fig><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Mean and SD of albumin, Ca, P, iPTH and pro-BNP of the patients</p></caption><graphic xlink:href="ABR-3-261-g006"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Statistical indicators of laboratory variables before the study</p></caption><graphic xlink:href="ABR-3-261-g007"/></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Mean and SD of Ca and P in different measurement points</p></caption><graphic xlink:href="ABR-3-261-g008"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>In patients with renal failure reduced level of vitamin D can be seen. Only 29% of patients with moderate renal failure, 17% with severe renal failure and 22% dialysis patients have sufficient vitamin D level.[<xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>] With regard to the existing evidence about the role of vitamin D on the cardiovascular system, the present study evaluated the effect of vitamin D on serum level of NT-pro-BNP in peritoneal dialysis patients. The results indicated that there was no significant difference between the group receiving vitamin D and the placebo group regarding pro-BNP level.</p><p>Bozic <italic>et al</italic>.[<xref rid="ref25" ref-type="bibr">25</xref>] chose 65 patients with low level of vitamin D (insufficient, &#x0003c;30 ng/ml) and New York Heart Association class I and II heart failure. They studied them regarding echocardiography, parathyroid hormone, 25(OH) vitamin D, NT-pro-BNP and adiponectin. Increase of heart failure class was associated with secondary hyperparathyroidism. Secondary hyperparathyroidism decreased left ventricular ejection fraction. Patients with congestive heart failure had higher levels of NT-pro-BNP, adiponectin and bone markers, while 25(OH) vitamin D level was decreased.[<xref rid="ref25" ref-type="bibr">25</xref>]</p><p>Measuring 25(OH) vitamin D level and BNP plasma level of patients undergoing chronic hemodialysis in Japan showed a relationship between BNP, pro-BNP and 25(OH) vitamin D level. In these patients, the plasma level of cardiac natriuretic peptides (specially type B level) represents the structural and functional cardiac involvement and it also determines the cardiovascular mortality.[<xref rid="ref26" ref-type="bibr">26</xref><xref rid="ref27" ref-type="bibr">27</xref>]</p><p>Tamez <italic>et al</italic>.[<xref rid="ref28" ref-type="bibr">28</xref>] study in America showed that treatment with 2 mg paricalcitol weekly for 48 weeks reduces cardiac hypertrophy indexes and BNP serum level.[<xref rid="ref28" ref-type="bibr">28</xref>] Wetmore <italic>et al</italic>.[<xref rid="ref29" ref-type="bibr">29</xref>] mentioned the relationship between nutritional deficiency of vitamin D with an increased level of NT-pro-BNP in dialysis patients with acute myocardial infarction.[<xref rid="ref29" ref-type="bibr">29</xref>] Park <italic>et al</italic>.[<xref rid="ref30" ref-type="bibr">30</xref>] in their study have reported that prescribed intravenous calcitriol 2 times a week for 15 weeks reduces the ventricular muscle loss and suppresses renin-angiotensin level II and ANP in chronic hemodialysis patients with secondary hyperparathyroidism.[<xref rid="ref30" ref-type="bibr">30</xref>] The mentioned studies suggest a relationship between the decrease of vitamin D level and increase of BNP in patients with chronic renal failure and dialysis patients.</p><p>There are also other studies, which have not reached these findings. Hur <italic>et al</italic>.[<xref rid="ref21" ref-type="bibr">21</xref>] examined the relationship between vitamin D level and cardiac biomarkers in dialysis patients. This study was conducted on 65 patients and the levels of 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D, cardiac troponin T and NT-pro-BNP were measured. There was a negative relationship between 25-hydroxy vitamin D level and cardiac troponin T (Spearman's rho = &#x02212;0.44, <italic>P</italic> &#x0003c; 0.01) but there was no relationship between vitamin D level and BNP (Spearman's rho = &#x02212;0.17, <italic>P</italic> = 0.17). There was no relationship between 1,25 dihydroxy vitamin D and both cardiac markers, cardiac troponin T and NT-pro-BNP.[<xref rid="ref31" ref-type="bibr">31</xref>] In a study by Saadi <italic>et al</italic>.[<xref rid="ref31" ref-type="bibr">31</xref>] there was no relationship between vitamin D level and NT-pro-BNP, which is the same as the present study.[<xref rid="ref31" ref-type="bibr">31</xref>]</p><p>Therefore, there are inconsistent results regarding the relationship between vitamin D level and cardiac biomarkers which show that further researches are needed. One reason for these differences might be the racial differences and dialysis modality. It can be concluded from the present study that prescribing oral vitamin D has no significant effect on serum level of pro-BNP of peritoneal dialysis patients.</p><p>Limitations of this study were as follows: First, measuring pro-BNP one times in the study; this measurement needs to be done in other levels and also in greater time intervals. Second, the lack of investigating echocardiographic parameters during the study, such as ventricular mass index which indicates the heart's condition and the effect of vitamin D on this matter. Therefore, to have more accurate findings, it is suggested that further research with larger sample size and applying the above mentioned notes be conducted in Iran.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Serum BNP level did not show any changes during vitamin D supplementation in patients on peritoneal dialysis.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank all the staff and patients of Peritoneal Dialysis Unit of Al-Zahra Hospital in Isfahan for their cooperation especially Mrs. Karimi and Mrs. Reihani and Dr. Baradaran Laboratory Center which assisted the study for laboratory measurements. In addition, we should appreciate Zahravi Pharmaceutical Factory that provide vitamin D pearls and the similar placebo.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoccali</surname><given-names>C</given-names></name><name><surname>Mallamaci</surname><given-names>F</given-names></name><name><surname>Benedetto</surname><given-names>FA</given-names></name><name><surname>Tripepi</surname><given-names>G</given-names></name><name><surname>Parlongo</surname><given-names>S</given-names></name><name><surname>Cataliotti</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients</article-title><source>J Am Soc Nephrol</source><year>2001</year><volume>12</volume><fpage>1508</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11423580</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarnak</surname><given-names>MJ</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Schoolwerth</surname><given-names>AC</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Culleton</surname><given-names>B</given-names></name><name><surname>Hamm</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>1050</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">14604997</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>JH</given-names></name><name><surname>Bell</surname><given-names>D</given-names></name><name><surname>Hensrud</surname><given-names>DD</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><article-title>Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>1949</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">19055985</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>D</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Zadshir</surname><given-names>A</given-names></name><name><surname>Tareen</surname><given-names>N</given-names></name><name><surname>Thadhani</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxy vitamin D in the United States: Data from the Third National Health and Nutrition Examination Survey</article-title><source>Arch Intern Med</source><year>2007</year><volume>167</volume><fpage>1159</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">17563024</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dusso</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Slatopolsky</surname><given-names>E</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Feldman</surname><given-names>D</given-names></name><name><surname>Pike</surname><given-names>JW</given-names></name><name><surname>Glorieux</surname><given-names>FH</given-names></name></person-group><article-title>Vitamin D and renal failure</article-title><source>Vitamin D</source><year>2005</year><edition>2nd ed</edition><publisher-loc>San Diego, CA</publisher-loc><publisher-name>Elsevier Academic</publisher-name><fpage>1313</fpage><lpage>38</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimura</surname><given-names>E</given-names></name><name><surname>Nishizawa</surname><given-names>Y</given-names></name><name><surname>Inaba</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Kawagishi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure</article-title><source>Kidney Int</source><year>1999</year><volume>55</volume><fpage>1019</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10027939</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannata-And&#x000ed;a</surname><given-names>JB</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>Alonso C</given-names></name></person-group><article-title>Vitamin D deficiency: A neglected aspect of disturbed calcium metabolism in renal failure</article-title><source>Nephrol Dial Transplant</source><year>2002</year><volume>17</volume><fpage>1875</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12401838</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Bernardini</surname><given-names>J</given-names></name><name><surname>Piraino</surname><given-names>B</given-names></name></person-group><article-title>Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients</article-title><source>Perit Dial Int</source><year>2005</year><volume>25</volume><fpage>362</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16022093</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidmon</surname><given-names>HJ</given-names></name><name><surname>Gutkowska</surname><given-names>J</given-names></name><name><surname>Murakami</surname><given-names>R</given-names></name><name><surname>Stumpf</surname><given-names>WE</given-names></name></person-group><article-title>Vitamin D receptors in heart: Effects on atrial natriuretic factor</article-title><source>Experientia</source><year>1991</year><volume>47</volume><fpage>958</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">1655516</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>NL</given-names></name><name><surname>Halabe</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>EF</given-names></name><name><surname>Sutton</surname><given-names>RA</given-names></name></person-group><article-title>The effect of calcitriol on atrial natriuretic factor release from isolated atrium</article-title><source>Metabolism</source><year>1991</year><volume>40</volume><fpage>135</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1824868</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Gardner</surname><given-names>DG</given-names></name></person-group><article-title>Negative regulation of the human atrial natriuretic peptide gene by 1,25-dihydroxyvitamin D3</article-title><source>J Biol Chem</source><year>1994</year><volume>269</volume><fpage>4934</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8106467</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Garami</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Gardner</surname><given-names>DG</given-names></name></person-group><article-title>1,25(OH) 2D3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes</article-title><source>Am J Physiol</source><year>1995</year><volume>268</volume><fpage>E1108</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">7611385</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Garami</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Gardner</surname><given-names>DG</given-names></name></person-group><article-title>1,25(OH) 2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes</article-title><source>J Clin Invest</source><year>1996</year><volume>97</volume><fpage>1577</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">8601621</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>Whitfield</surname><given-names>GK</given-names></name><name><surname>Jurutka</surname><given-names>PW</given-names></name><name><surname>Haussler</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Suppression of ANP gene transcription by liganded vitamin D receptor: Involvement of specific receptor domains</article-title><source>Hypertension</source><year>1998</year><volume>31</volume><fpage>1338</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9622151</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>SC</given-names></name><name><surname>McGregor</surname><given-names>DO</given-names></name><name><surname>Macaskill</surname><given-names>P</given-names></name><name><surname>Craig</surname><given-names>JC</given-names></name><name><surname>Elder</surname><given-names>GJ</given-names></name><name><surname>Strippoli</surname><given-names>GF</given-names></name></person-group><article-title>Meta-analysis: Vitamin D compounds in chronic kidney disease</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><fpage>840</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18087055</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>ZF</given-names></name><name><surname>Liu</surname><given-names>SQ</given-names></name><name><surname>Cao</surname><given-names>LP</given-names></name></person-group><article-title>1,25-Dihydroxyvitamin D (3) is a negative endocrine regulator of the renin-angiotensin system</article-title><source>J Clin Invest</source><year>2002</year><volume>110</volume><fpage>229</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">12122115</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>W</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>LP</given-names></name><name><surname>Qiao</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><etal/></person-group><article-title>Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><fpage>E125</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15367398</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishikimi</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>N</given-names></name><name><surname>Horii</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><etal/></person-group><article-title>Direct immunochemiluminescent assay for proBNP and total BNP in human plasma proBNP and total BNP levels in normal and heart failure</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e53233</fpage><pub-id pub-id-type="pmid">23365636</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfatto</surname><given-names>G</given-names></name><name><surname>Corticelli</surname><given-names>A</given-names></name><name><surname>Villani</surname><given-names>A</given-names></name><name><surname>Giglio</surname><given-names>A</given-names></name><name><surname>Della Rosa</surname><given-names>F</given-names></name><name><surname>Branzi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Transthoracic bioimpedance and brain natriuretic peptide assessment for prognostic stratification of outpatients with chronic systolic heart failure</article-title><source>Clin Cardiol</source><year>2013</year><volume>36</volume><fpage>103</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23377871</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pastural-Thaunat</surname><given-names>M</given-names></name><name><surname>Ecochard</surname><given-names>R</given-names></name><name><surname>Boumendjel</surname><given-names>N</given-names></name><name><surname>Abdullah</surname><given-names>E</given-names></name><name><surname>Cardozo</surname><given-names>C</given-names></name><name><surname>Lenz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relative change in NT-proBNP Level: An important risk predictor of cardiovascular congestion in haemodialysis patients</article-title><source>Nephron Extra</source><year>2012</year><volume>2</volume><fpage>311</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23341833</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>DM</given-names></name><name><surname>Lim</surname><given-names>KH</given-names></name><name><surname>Yoon</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Vitamin D levels and their relationship with cardiac biomarkers in chronic hemodialysis patients</article-title><source>J Korean Med Sci</source><year>2009</year><volume>24</volume><issue>Suppl</issue><fpage>S109</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">19194538</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson-Hughes</surname><given-names>B</given-names></name><name><surname>Heaney</surname><given-names>RP</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Meunier</surname><given-names>PJ</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name></person-group><article-title>Estimates of optimal vitamin D status</article-title><source>Osteoporos Int</source><year>2005</year><volume>16</volume><fpage>713</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15776217</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaClair</surname><given-names>RE</given-names></name><name><surname>Hellman</surname><given-names>RN</given-names></name><name><surname>Karp</surname><given-names>SL</given-names></name><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>Ofner</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>45</volume><fpage>1026</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15957131</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Gutierrez</surname><given-names>O</given-names></name><name><surname>Ankers</surname><given-names>E</given-names></name><name><surname>Monroy</surname><given-names>M</given-names></name><name><surname>Tamez</surname><given-names>H</given-names></name><etal/></person-group><article-title>Vitamin D levels and early mortality among incident hemodialysis patients</article-title><source>Kidney Int</source><year>2007</year><volume>72</volume><fpage>1004</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">17687259</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozic</surname><given-names>B</given-names></name><name><surname>Loncar</surname><given-names>G</given-names></name><name><surname>Prodanovic</surname><given-names>N</given-names></name><name><surname>Lepic</surname><given-names>T</given-names></name><name><surname>Radojicic</surname><given-names>Z</given-names></name><name><surname>Cvorovic</surname><given-names>V</given-names></name><etal/></person-group><article-title>Parathyroid hormone response to vitamin D insufficiency in elderly males with chronic heart failure</article-title><source>Physiol Res</source><year>2011</year><volume>60</volume><issue>Suppl 1</issue><fpage>S155</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21777017</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Willnow</surname><given-names>T</given-names></name><name><surname>Nykjaer</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Feldman</surname><given-names>D</given-names></name><name><surname>Pike</surname><given-names>JW</given-names></name><name><surname>Glorieux</surname><given-names>FH</given-names></name></person-group><article-title>Endocytic pathways for 25-(OH) vitamin D3</article-title><source>Vitamin D</source><year>2005</year><edition>2nd ed</edition><publisher-loc>San Diego, CA</publisher-loc><publisher-name>Elsevier Academic</publisher-name><fpage>153</fpage><lpage>66</lpage></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naganuma</surname><given-names>T</given-names></name><name><surname>Sugimura</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>S</given-names></name><name><surname>Yasumoto</surname><given-names>R</given-names></name><name><surname>Sugimura</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>C</given-names></name><etal/></person-group><article-title>The prognostic role of brain natriuretic peptides in hemodialysis patients</article-title><source>Am J Nephrol</source><year>2002</year><volume>22</volume><fpage>437</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12381941</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamez</surname><given-names>H</given-names></name><name><surname>Zoccali</surname><given-names>C</given-names></name><name><surname>Packham</surname><given-names>D</given-names></name><name><surname>Wenger</surname><given-names>J</given-names></name><name><surname>Bhan</surname><given-names>I</given-names></name><name><surname>Appelbaum</surname><given-names>E</given-names></name><etal/></person-group><article-title>Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease</article-title><source>Am Heart J</source><year>2012</year><volume>164</volume><fpage>902</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">23194491</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetmore</surname><given-names>JB</given-names></name><name><surname>Gadi</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>JH</given-names></name><name><surname>Chan</surname><given-names>PS</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: A cross-sectional analysis</article-title><source>BMC Res Notes</source><year>2011</year><volume>4</volume><fpage>542</fpage><pub-id pub-id-type="pmid">22171582</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>CW</given-names></name><name><surname>Oh</surname><given-names>YS</given-names></name><name><surname>Shin</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>CM</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism</article-title><source>Am J Kidney Dis</source><year>1999</year><volume>33</volume><fpage>73</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9915270</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saadi</surname><given-names>HF</given-names></name><name><surname>Nicholls</surname><given-names>MG</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Benedict</surname><given-names>S</given-names></name><name><surname>Yasin</surname><given-names>J</given-names></name></person-group><article-title>Serum 25-hydroxyvitamin D is not related to cardiac natriuretic peptide in nulliparous and lactating women</article-title><source>BMC Endocr Disord</source><year>2009</year><volume>9</volume><fpage>4</fpage><pub-id pub-id-type="pmid">19178708</pub-id></element-citation></ref></ref-list></back></article>